IM19 CAR-T cell therapy for IgA and membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new cell therapy (IM19 CAR-T) for people with two types of kidney disease: IgA nephropathy or primary membranous nephropathy. The goal is to see if these specially engineered immune cells can reduce kidney damage and slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need a kidney biopsy that shows you have IgA nephropathy or primary membranous nephropathy.
- Your urine must contain a certain amount of protein (at least 0.5g/gCr for IgA or >4g/24h for membranous).
- Your kidney function (eGFR) should be between 20 and 60 mL/min for IgA nephropathy.
- You cannot have had immune-suppressing drugs for your kidney disease in the last 3 months (or certain steroid doses).
- You must have adequate liver, heart, and lung function as checked by standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a universal cell therapy called GT719 that targets CD19 on B cells to treat several immune-mediated kidney diseases, including IgA nephropathy, ANCA vasculitis, membranous nephropathy, and others. It may help people who have not responded well to standard treatments.
This early-stage trial tests a new type of immune cell therapy (CAR-γδ T cells) designed to treat three types of autoimmune kidney disease that haven't responded well to standard treatments. The goal is to see if this experimental therapy can reduce kidney damage and help patients avoid kidney failure.
This trial tests a new type of cell therapy (called UCAR-T) that targets two proteins on immune cells to help calm the immune system and reduce kidney damage in people with a tough-to-treat form of membranous nephropathy. It’s for patients who haven’t gotten better with standard treatments and have high levels of protein leaking into their urine.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This trial tests whether IM19 can safely and effectively treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It is for adults with certain lymphoma markers and good overall functioning.
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.